Citius Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| CITIUS PHARMACEUTICALS, INC. | ||
| Date: December 27, 2024 | By: | /s/ Leonard Mazur |
|---|---|---|
| Leonard Mazur | ||
| Chief Executive Officer (Principal Executive Officer) | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Leonard Mazur | Chief Executive Officer and Director | December 27, 2024 |
| Leonard Mazur | (Principal Executive Officer) | |
| /s/ Myron Holubiak | Executive Vice Chairman and Director | December 27, 2024 |
| Myron Holubiak | ||
| /s/ Jaimie Bartushak | Chief Financial Officer | December 27, 2024 |
| Jaime Bartushak | (Principal Financial Officer and Principal Accounting Officer) | |
| /s/ Suren Dutia | Director | December 27, 2024 |
| Suren Dutia | ||
| /s/ Carol Webb | Director | December 27, 2024 |
| Carol Webb | ||
| /s/ Eugene Holuka | Director | December 27, 2024 |
| Eugene Holuka | ||
| /s/ Dennis McGrath | Director | December 27, 2024 |
| Dennis McGrath | ||
| /s/ Robert J. Smith | Director | December 27, 2024 |
| Robert J. Smith | ||
CONSOLIDATED FINANCIAL STATEMENTS
INDEX
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID #392) | F-2 |
|---|---|
| Consolidated Balance Sheets | F-3 |
| Consolidated Statements of Operations | F-4 |
| Consolidated Statements of Changes in Stockholders’ Equity | F-5 |
| Consolidated Statements of Cash Flows | F-6 |
| Notes to Consolidated Financial Statements | F-7 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.